GenEdit is focused on overcoming the major challenge to genetic medicines:  Delivery. We aim to overcome this limitation and enable treatment of a broad range of diseases, having a positive impact on the lives of as many people as possible.  

The foundation of our company is our NanoGalaxy platform. NanoGalaxy contains a library spanning thousands of unique non-viral, non-lipid, polymer nanoparticles. Using our iterative screening process, we are able to identify polymer nanoparticles that can deliver the needed genetic medicine payload to the needed tissue to treat disease.

We are focusing our research on the treatment of diseases for which our delivery technology can enable therapeutic options that otherwise may not be possible. We are developing an internal pipeline of therapeutic candidates to treat a range of diseases with high unmet medical need.


Qiming Venture Partners

SkyDeck Berkeley

Sequoia Capital

Bow Capital

SK Holdings

DCVC Bio

ACVC

Huons

Pathway Partners

Terra VC

Dong-A ST

K2 Investment Partners

KIMCO

Korea Development Bank

loftyrock investment

Mirae Asset Venture Investment

Company K Partners

IMM Investment

Time Folio Asset Management

Timepolio Asset Management

Dayli Partners

Korea Investment Partners

DAOL Investment & Securities

KTB Network

GenEdit

We held an exciting GenEdit Day, which is a recurring event to gather and review our company progress. This year we celebrated our partnership with Genentech, reviewed our latest data and finished the day with a fun team-building activity.


We're excited to announce a collaboration with Genentech to discover and develop novel nanoparticles with our #Nanogalaxy platform to deliver Genentech’s nucleic acid-based medicines for treatment of #autoimmunedisease. 

Read the release here: https://lnkd.in/gvh8J4T6

#geneticmedicines

We are pleased to announce that the GenEdit team is a Phase I winner of the National Institutes of Health TARGETED Challenge for programmable delivery systems for gene editing. The award is a recognition of the potential of our NanoGalaxy® platform for a broad range of genetic medicines for multiple therapy areas.


An alternative gene editing technology to CRISPR Cas9, focusing on recombineering.

Retron Library Recombineering (RLR) Platform

A competitor to CRISPR Cas9, specializing in CLOVER nucleases for gene editing.

Cas-CLOVER Nucleases

A gene editing technology company focused on zinc finger nucleases for precise genome modifications.

Zinc Finger Nucleases

A company utilizing CRISPR genome editing technology for the discovery and development of novel therapeutic candidates.

Synthego

Known for its innovative base editing technology, enabling precise modifications of DNA.

Beam Therapeutics

A gene therapy company with the potential to transform the medical industry.

Bluebird Bio

A gene therapy company with innovative approaches to medical treatments.

4D Molecular Therapeutics

A company focused on gene therapy with potential transformative impact on the medical industry.

Genprex, Inc.

A gene therapy company with innovative medical applications.

Poseida Therapeutics

A leading company in the global genome editing market, offering a wide range of genome editing solutions.

Thermo Fisher Scientific

A prominent player in the global genome editing market, known for its contributions to the field.

Merck KGaA

A key player in the global genome editing market, offering various genome editing solutions.

GenScript

A company specializing in genome editing technologies for therapeutic applications.

Sangamo Therapeutics

GeneEdit is a biotechnology company focused on developing next-generation gene editing technologies for therapeutic applications. Their proprietary platform aims to enable safer and more precise genome editing for the treatment of various genetic diseases.

GeneEdit

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	May 11, 2024 8:41 AM	3c3a2403
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	May 11, 2024 8:57 AM	89e1d983
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	79e9fc23
crunchbase profile	general
li profile	general	May 11, 2024 8:41 AM	033164fd
translate crunchbase fundingrounds	general
peers	general
news basic	general	May 11, 2024 8:41 AM	7d9c911f
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:GENEDIT

GeneEdit